A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Authors
Hamid, OIlaria, R
Garbe, C
Wolter, P
Maio, M
Hutson, T
Arance, A
Lorigan, Paul C
Lee, J
Hauschild, A
Mohr, P
Hahka-Kemppinen, M
Kaiser, C
Turner, P
Conti, I
Grob, J
Affiliation
The Angeles Clinic and Research Institute, Los Angeles, California.Issue Date
2014-07-01
Metadata
Show full item recordAbstract
Tasisulam sodium (hereafter referred to as tasisulam) is a novel, highly albumin-bound agent that demonstrated activity in a phase 2 melanoma study.Citation
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. 2014, 120 (13):2016-24 CancerJournal
CancerDOI
10.1002/cncr.28635PubMed ID
24676877Type
ArticleLanguage
enISSN
1097-0142ae974a485f413a2113503eed53cd6c53
10.1002/cncr.28635
Scopus Count
Collections
Related articles
- A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.
- Authors: Kirkwood JM, Gonzalez R, Reintgen D, Clingan PR, McWilliams RR, de Alwis DP, Zimmermann A, Brown MP, Ilaria RL Jr, Millward MJ
- Issue date: 2011 Oct 15
- Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study.
- Authors: Scagliotti GV, Ilaria R Jr, Novello S, von Pawel J, Fischer JR, Ermisch S, de Alwis DP, Andrews J, Reck M, Crino L, Eschbach C, Manegold C
- Issue date: 2012 Jun
- A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.
- Authors: Gordon MS, Ilaria R Jr, de Alwis DP, Mendelson DS, McKane S, Wagner MM, Look KY, LoRusso PM
- Issue date: 2013 Jan
- A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.
- Authors: Ryan CW, Matias C, Agulnik M, Lopez-Pousa A, Williams C, de Alwis DP, Kaiser C, Miller MA, Ermisch S, Ilaria R Jr, Keohan ML
- Issue date: 2013 Feb
- A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
- Authors: Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R
- Issue date: 2010 Jan 1